BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
Policy, regulations, AI and CRDMO take centre stage at the flagship event of the Department of Pharmaceuticals
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
The new test offers a minimally invasive blood-based approach to tracking neurological damage, measuring neurofilament light chain
The three-day conference is expected to bring together more than 3,000 physiotherapists, clinicians, researchers, academicians, and students
These surgeries involve no bone cuts, minimal surgical trauma, smaller incisions and significantly reduced blood loss
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
The approval now covers procedures using 10-14F inner diameter and up to 17F outer diameter procedural sheaths
The new single-pill therapy combines cilnidipine, telmisartan and metoprolol, bringing together three established antihypertensive agents with complementary mechanisms
The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets
Subscribe To Our Newsletter & Stay Updated
